HRP20140019T4 - Smjese i sredstva za dijagnozu mikrobnih infekcija - Google Patents
Smjese i sredstva za dijagnozu mikrobnih infekcija Download PDFInfo
- Publication number
- HRP20140019T4 HRP20140019T4 HRP20140019TT HRP20140019T HRP20140019T4 HR P20140019 T4 HRP20140019 T4 HR P20140019T4 HR P20140019T T HRP20140019T T HR P20140019TT HR P20140019 T HRP20140019 T HR P20140019T HR P20140019 T4 HRP20140019 T4 HR P20140019T4
- Authority
- HR
- Croatia
- Prior art keywords
- chloro
- indolyl
- bromo
- platform according
- galactopyranoside
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 18
- 230000000813 microbial effect Effects 0.000 title claims 6
- 208000015181 infectious disease Diseases 0.000 title claims 2
- 239000007787 solid Substances 0.000 claims 10
- 239000004599 antimicrobial Substances 0.000 claims 7
- OQWBAXBVBGNSPW-RKQHYHRCSA-N (2s,3r,4s,5s,6r)-2-[(6-chloro-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC(Cl)=CC=C12 OQWBAXBVBGNSPW-RKQHYHRCSA-N 0.000 claims 6
- OPIFSICVWOWJMJ-LNNRFACYSA-N 5-bromo-4-chloro-3-indolyl beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-LNNRFACYSA-N 0.000 claims 6
- 239000002609 medium Substances 0.000 claims 6
- 239000000758 substrate Substances 0.000 claims 6
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- DHJFFLKPAYHPHU-BYNIDDHOSA-N 5-bromo-4-chloro-3-indolyl beta-D-glucuronide Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 DHJFFLKPAYHPHU-BYNIDDHOSA-N 0.000 claims 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 4
- 229920001817 Agar Polymers 0.000 claims 4
- -1 Cefkinome Chemical compound 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 4
- 239000008272 agar Substances 0.000 claims 4
- 229940024554 amdinocillin Drugs 0.000 claims 4
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 claims 4
- 239000003593 chromogenic compound Substances 0.000 claims 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 4
- 239000008107 starch Substances 0.000 claims 4
- 235000019698 starch Nutrition 0.000 claims 4
- 229960005256 sulbactam Drugs 0.000 claims 4
- 241000588724 Escherichia coli Species 0.000 claims 3
- 241000191967 Staphylococcus aureus Species 0.000 claims 3
- 229960000723 ampicillin Drugs 0.000 claims 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 3
- 229960003324 clavulanic acid Drugs 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 3
- 229960001082 trimethoprim Drugs 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- CHRVKCMQIZYLNM-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-6-chloro-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC(Cl)=C(Br)C=C12 CHRVKCMQIZYLNM-MBJXGIAVSA-N 0.000 claims 2
- CJNPEPJBIHGEMU-UHFFFAOYSA-N (5-bromo-6-chloro-1h-indol-3-yl) dihydrogen phosphate Chemical compound ClC1=C(Br)C=C2C(OP(O)(=O)O)=CNC2=C1 CJNPEPJBIHGEMU-UHFFFAOYSA-N 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- 239000001888 Peptone Substances 0.000 claims 2
- 108010080698 Peptones Proteins 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000004098 Tetracycline Substances 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 229960003022 amoxicillin Drugs 0.000 claims 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 2
- 235000015278 beef Nutrition 0.000 claims 2
- 239000005018 casein Substances 0.000 claims 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 2
- 235000021240 caseins Nutrition 0.000 claims 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims 2
- 229960005361 cefaclor Drugs 0.000 claims 2
- 229960004841 cefadroxil Drugs 0.000 claims 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims 2
- 229960004682 cefoperazone Drugs 0.000 claims 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims 2
- 229940106164 cephalexin Drugs 0.000 claims 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
- 239000012153 distilled water Substances 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 229940124307 fluoroquinolone Drugs 0.000 claims 2
- 229960000308 fosfomycin Drugs 0.000 claims 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims 2
- 229960001031 glucose Drugs 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 229960000564 nitrofurantoin Drugs 0.000 claims 2
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims 2
- 229940124588 oral cephalosporin Drugs 0.000 claims 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 2
- 235000019319 peptone Nutrition 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims 2
- 229960005404 sulfamethoxazole Drugs 0.000 claims 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims 2
- 235000019364 tetracycline Nutrition 0.000 claims 2
- 150000003522 tetracyclines Chemical class 0.000 claims 2
- 229960004089 tigecycline Drugs 0.000 claims 2
- 229940075420 xanthine Drugs 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- LZFNFLTVAMOOPJ-PZRMXXKTSA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-methylsulfanyloxane-3,4,5-triol Chemical compound CS[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LZFNFLTVAMOOPJ-PZRMXXKTSA-N 0.000 claims 1
- MIAKOEWBCMPCQR-YBXAARCKSA-N (2s,3r,4s,5r,6r)-2-(4-aminophenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C1=CC(N)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MIAKOEWBCMPCQR-YBXAARCKSA-N 0.000 claims 1
- OSNSWKAZFASRNG-WNFIKIDCSA-N (2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;hydrate Chemical compound O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O OSNSWKAZFASRNG-WNFIKIDCSA-N 0.000 claims 1
- KMEGBUCIGMEPME-LQYKFRDPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylic acid Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 KMEGBUCIGMEPME-LQYKFRDPSA-N 0.000 claims 1
- XWMVMWTVLSLJGY-FAJPTIRJSA-N (2s,5r,6r)-6-[[(2r)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 XWMVMWTVLSLJGY-FAJPTIRJSA-N 0.000 claims 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 claims 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 claims 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 claims 1
- YUXQJAVLCFEZCS-UHFFFAOYSA-N 5-bromo-6-[3-(hydroxymethyl)piperidin-1-yl]-1h-pyrimidine-2,4-dione Chemical compound C1C(CO)CCCN1C1=NC(O)=NC(O)=C1Br YUXQJAVLCFEZCS-UHFFFAOYSA-N 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- 241000974482 Aricia saepiolus Species 0.000 claims 1
- 108010001478 Bacitracin Proteins 0.000 claims 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 108010020326 Caspofungin Proteins 0.000 claims 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 claims 1
- 241000588923 Citrobacter Species 0.000 claims 1
- 241000873310 Citrobacter sp. Species 0.000 claims 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- 206010018612 Gonorrhoea Diseases 0.000 claims 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims 1
- BPHPUYQFMNQIOC-ZEBDFXRSSA-N Isopropyl 1-thio-beta-D-glucopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-ZEBDFXRSSA-N 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims 1
- 108010028921 Lipopeptides Proteins 0.000 claims 1
- 208000034762 Meningococcal Infections Diseases 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 241000588772 Morganella morganii Species 0.000 claims 1
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000035109 Pneumococcal Infections Diseases 0.000 claims 1
- 241000588770 Proteus mirabilis Species 0.000 claims 1
- 241000588767 Proteus vulgaris Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 229930189077 Rifamycin Natural products 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 206010062255 Soft tissue infection Diseases 0.000 claims 1
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 108010034396 Streptogramins Proteins 0.000 claims 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 1
- 239000004182 Tylosin Substances 0.000 claims 1
- 229930194936 Tylosin Natural products 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 108010080702 Virginiamycin Proteins 0.000 claims 1
- 239000004188 Virginiamycin Substances 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 229940072174 amphenicols Drugs 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 229960003942 amphotericin b Drugs 0.000 claims 1
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 claims 1
- 229950006334 apramycin Drugs 0.000 claims 1
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- 229960003071 bacitracin Drugs 0.000 claims 1
- 229930184125 bacitracin Natural products 0.000 claims 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 239000004227 calcium gluconate Substances 0.000 claims 1
- 235000013927 calcium gluconate Nutrition 0.000 claims 1
- 229960004494 calcium gluconate Drugs 0.000 claims 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims 1
- 229960003034 caspofungin Drugs 0.000 claims 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims 1
- 229960000603 cefalotin Drugs 0.000 claims 1
- 229960001139 cefazolin Drugs 0.000 claims 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 1
- 229960003719 cefdinir Drugs 0.000 claims 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims 1
- 229960002100 cefepime Drugs 0.000 claims 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims 1
- 229960002129 cefixime Drugs 0.000 claims 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims 1
- 229960003791 cefmenoxime Drugs 0.000 claims 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 claims 1
- 229960004261 cefotaxime Drugs 0.000 claims 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims 1
- 229960002682 cefoxitin Drugs 0.000 claims 1
- 229960000466 cefpirome Drugs 0.000 claims 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 claims 1
- 229960005090 cefpodoxime Drugs 0.000 claims 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims 1
- 229960002580 cefprozil Drugs 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 claims 1
- 229960004086 ceftibuten Drugs 0.000 claims 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 claims 1
- 229960001668 cefuroxime Drugs 0.000 claims 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims 1
- 229910000361 cobalt sulfate Inorganic materials 0.000 claims 1
- 229940044175 cobalt sulfate Drugs 0.000 claims 1
- KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 claims 1
- 229910000365 copper sulfate Inorganic materials 0.000 claims 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 229960003722 doxycycline Drugs 0.000 claims 1
- 229960000740 enrofloxacin Drugs 0.000 claims 1
- 229940032049 enterococcus faecalis Drugs 0.000 claims 1
- 229960002770 ertapenem Drugs 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 229960004273 floxacillin Drugs 0.000 claims 1
- 229960004884 fluconazole Drugs 0.000 claims 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004413 flucytosine Drugs 0.000 claims 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 1
- 229960004675 fusidic acid Drugs 0.000 claims 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims 1
- 229960001430 garenoxacin Drugs 0.000 claims 1
- NJDRXTDGYFKORP-LLVKDONJSA-N garenoxacin Chemical compound N([C@@H](C1=CC=2)C)CC1=CC=2C(C=1OC(F)F)=CC=C(C(C(C(O)=O)=C2)=O)C=1N2C1CC1 NJDRXTDGYFKORP-LLVKDONJSA-N 0.000 claims 1
- 229960003923 gatifloxacin Drugs 0.000 claims 1
- 229960003170 gemifloxacin Drugs 0.000 claims 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 229960002182 imipenem Drugs 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- 229910000358 iron sulfate Inorganic materials 0.000 claims 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960005287 lincomycin Drugs 0.000 claims 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims 1
- 229940041028 lincosamides Drugs 0.000 claims 1
- 229960003907 linezolid Drugs 0.000 claims 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims 1
- 229960001977 loracarbef Drugs 0.000 claims 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 239000011742 magnesium glycerophosphate Substances 0.000 claims 1
- 235000001130 magnesium glycerophosphate Nutrition 0.000 claims 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 1
- 235000019341 magnesium sulphate Nutrition 0.000 claims 1
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 claims 1
- 235000013372 meat Nutrition 0.000 claims 1
- 239000013028 medium composition Substances 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- HOVAGTYPODGVJG-PZRMXXKTSA-N methyl alpha-D-galactoside Chemical compound CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-PZRMXXKTSA-N 0.000 claims 1
- HOVAGTYPODGVJG-VOQCIKJUSA-N methyl beta-D-galactoside Chemical compound CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-VOQCIKJUSA-N 0.000 claims 1
- HOVAGTYPODGVJG-XUUWZHRGSA-N methyl beta-D-glucopyranoside Chemical compound CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-XUUWZHRGSA-N 0.000 claims 1
- DICCNWCUKCYGNF-MDMQIMBFSA-N methyl beta-D-glucopyranuronate Chemical compound COC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O DICCNWCUKCYGNF-MDMQIMBFSA-N 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960000198 mezlocillin Drugs 0.000 claims 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- 229940076266 morganella morganii Drugs 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 229960003128 mupirocin Drugs 0.000 claims 1
- 229930187697 mupirocin Natural products 0.000 claims 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims 1
- 229960000210 nalidixic acid Drugs 0.000 claims 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims 1
- 150000004957 nitroimidazoles Chemical class 0.000 claims 1
- 229940014662 pantothenate Drugs 0.000 claims 1
- 235000019161 pantothenic acid Nutrition 0.000 claims 1
- 239000011713 pantothenic acid Substances 0.000 claims 1
- 235000019371 penicillin G benzathine Nutrition 0.000 claims 1
- 229940056360 penicillin g Drugs 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920000307 polymer substrate Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229940007042 proteus vulgaris Drugs 0.000 claims 1
- 235000008160 pyridoxine Nutrition 0.000 claims 1
- 239000011677 pyridoxine Substances 0.000 claims 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 229960003292 rifamycin Drugs 0.000 claims 1
- 239000011833 salt mixture Substances 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- YVOFSHPIJOYKSH-NLYBMVFSSA-M sodium rifomycin sv Chemical compound [Na+].OC1=C(C(O)=C2C)C3=C([O-])C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O YVOFSHPIJOYKSH-NLYBMVFSSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 229940041030 streptogramins Drugs 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 229940040944 tetracyclines Drugs 0.000 claims 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- 235000019157 thiamine Nutrition 0.000 claims 1
- 239000011721 thiamine Substances 0.000 claims 1
- 229960004659 ticarcillin Drugs 0.000 claims 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 229960000281 trometamol Drugs 0.000 claims 1
- 229960000497 trovafloxacin Drugs 0.000 claims 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 claims 1
- 239000012137 tryptone Substances 0.000 claims 1
- 229960004059 tylosin Drugs 0.000 claims 1
- 235000019375 tylosin Nutrition 0.000 claims 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
- 229960003842 virginiamycin Drugs 0.000 claims 1
- 235000019373 virginiamycin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000012711 vitamin K3 Nutrition 0.000 claims 1
- 239000011652 vitamin K3 Substances 0.000 claims 1
- 229940011671 vitamin b6 Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 229940041603 vitamin k 3 Drugs 0.000 claims 1
- 229960004740 voriconazole Drugs 0.000 claims 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 1
- 229910000368 zinc sulfate Inorganic materials 0.000 claims 1
- 229960001763 zinc sulfate Drugs 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/14—Streptococcus; Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/34—Internal compartments or partitions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
- C12M41/36—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of biomass, e.g. colony counters or by turbidity measurements
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/46—Means for regulation, monitoring, measurement or control, e.g. flow regulation of cellular or enzymatic activity or functionality, e.g. cell viability
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/045—Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
- C12Q1/08—Quantitative determination using multifield media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/10—Petri dish
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/12—Well or multiwell plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/348—Urinary tract infections
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Sustainable Development (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Clinical Laboratory Science (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (28)
1. Platforma koja obuhvaća čvrstu podlogu, pri čemu ta čvrsta podloga ima udubljenje koje može poslužiti kao dio u koji se stavlja uzorak moguće mikrobno inficiran ili onečišćen, to udubljenje podijeljeno je na tri ili više odjeljka, svaki odjeljak sadrži testnu smjesu ili kontrolnu smjesu, te jedan ili više integriranih razdjelnika koji dijele to udubljenje u spomenute zasebne odjeljke, gdje
i) testna smjesa sadrži polučvrsti medij za rast mikroba, antimikrobno sredstvo
i
tri ili više kromogena supstrata izabrana iz grupe koja obuhvaća 5-Brom-6-klor-3-indolil fosfat, 5-Brom-4-klor-3-indolil-β-D-galaktopiranozid, 5-Brom-6-klor-3-indolil-β-D-galaktopiranozid, 6-Klor-3-indolil-β-D-galaktopiranozid, 5-Brom-4-klor-3-indolil-β-D-glukopiranozid, 5-Brom-4-klor-3-indolil-β-D-glukuronid;
ii) pri čemu svaka testna smjesa sadrži drugačije antimikrobno sredstvo;
iii) kontrolna smjesa sadrži isti polučvrsti medij za rast mikroba i iste kromogene supstrate kao testna smjesa, ali ne sadrži antimikrobno sredstvo kako je definirano pod i);
i gdje taj polučvrsti medij za rast mikroba sadrži triptofan i jedan ili više induktora; gdje platforma obuhvaća kontrolni spoj.
2. Platforma prema zahtjevu 1, gdje se antimikrobno sredstvo u testnoj smjesi izabire iz grupe koja obuhvaća aminoglikozide, ansamicine, beta-laktamske antibiotike, glikopeptide, makrolide, linkozamide, polipeptide, kinolone, sulfonamide, tetracikline, cikličke lipopeptide, glicilcikline, oksazolidinone, diaminopirimidine, nitrofurane, rifamicin, antibiotske peptide, amfenikole, nitroimidazole, streptogramine i fosfomicine.
3. Platforma prema zahtjevu 1 ili zahtjevu 2, gdje je smjesa prisutna u svakom od odjeljaka u količini koja odgovara od 25-45% volumena odjeljka.
4. Platforma prema bilo kojem od zahtjeva 1 do 3, ta platforma ima 7 ili više odjeljaka.
5. Platforma prema bilo kojem od zahtjeva 1 do 4, gdje su odjeljci razdvojeni pomoću razdjelnika koji su obrađeni na način da se spriječi difuzija antimikrobnog sredstva između odjeljaka.
6. Platforma prema bilo kojem od zahtjeva 1 do 5, gdje je spomenuta čvrsta podloga proizvedena od plastičnog/polimernog supstrata, od staklenog supstrata ili metalnog supstrata.
7. Platforma prema bilo kojem od zahtjeva 1 do 6, gdje je ta čvrsta podloga Petrijeva zdjelica, po izboru ima promjer od 80 do 100 mm.
8. Platforma prema bilo kojem od zahtjeva 1 do 7, gdje svaki od odjeljaka u kojem je testna smjesa ima površinu od 4-9 cm2 i/ili gdje odjeljak s kontrolnom smjesom ima površinu od 15-25 cm2.
9. Platforma prema bilo kojem od zahtjeva 1 do 8, gdje su jedan ili više induktora prisutni u testnoj smjesi i kontrolnoj smjesi u količinama od 0.001 do 1.0 g/l.
10. Platforma prema bilo kojem od zahtjeva 1 do 9, gdje se taj jedan ili više induktora izabiru iz grupe koja obuhvaća 4-aminofenil-β-D-galaktopiranozid, izopropil -β-D-tiogalaktopiranozid, 1-O-Metil-β-D-galaktopiranozid, Metil-β-D-tiogalaktopiranozid, 1-O-Metil-α-D-galaktopiranozid, Izopropil-β-D-tioglukopiranozid, 1-O-metil-β-D-glukopiranozid, Izopropil-β-D-tioglukuronsku kiselinu i natrijevu sol 1-O-Metil-β-D-glukuronske kiseline.
11. Platforma prema bilo kojem od zahtjeva 1 do 10, gdje
i) kolonije E. coli, ako su prisutne, pojavit će se obojane losos-crveno/ružičasto;
ii) kolonije Citrobacter sp., ako su prisutne, pojavit će se obojane zelenkasto-plavo;
iii) kolonije Klebsiella, Enterobacter ili Citrobacter spp., ako su prisutne, pojavit će se obojane tamno plavo;
iv) kolonije Proteus mirabilis/Morganella morganii, ako su prisutne, pojavit će se obojane svijetlo smeđe;
v) kolonije Proteus vulgaris, ako su prisutne, pojavit će se obojane tamno zeleno;
vi) kolonije Enterococcus faecalis ili Enterococcus faecium, ako su prisutne, pojavit će se obojane zelenkasto ili plavo;
vii) kolonije Staphilococcus saprophyticus, ako su prisutne, pojavit će se obojane crveno ili losos-crveno;
viii) kolonije Staphilococcus ili Pseudomonas aeruginosa, ako su prisutne, pojavit će se obojane bijelo ili žuto; i
ix) kolonije Candida spp., ako su prisutne, pojavit će se obojane bijelo.
12. Platforma prema bilo kojem od zahtjeva 1 do 11, gdje se antimikrobno sredstvo izabire iz grupe koja obuhvaća Amikacin, Amoksicilin, Amoksicilin-klavulansku kiselinu, Amfotericin-B, Ampicilin, Ampicilin-Sulbaktam, Apramicin, Azitromicin, Aztreonam, Bacitracin, Benzilpenicilin, Kaspofungin, Cefaklor, Cefadroksil, Cefaleksin, Cefalotin, Cefazolin, Cefdinir, Cefepim, Cefiksim, Cefmenoksim, Cefoperazon, Cefoperazon/Sulbaktam, Cefotaksim, Cefoksitin, Cefpirom, Cefpodoksim, Cefpodoksim-klavulansku kiselinu, Cefpodoksim-sulbaktam, Cefprozil, Cefkinom, Ceftazidim, Ceftibuten, Ceftiofur, Ceftobiprol, Ceftriakson, Cefuroksim, Kloramfenikol, Florfenikol, Ciprofloksacin (ili drugi fluorokinolon) klaritromicin, klinafloksacin, klindamicin, kloksacilin, kolistin, kotrimoksazol (Trimetoprim/sulfametoksazol), Dalbavancin, Dalfopristin/kinupristin, Daptomicin, Dibekacin, Dikloksacilin, Doripenem, Doksiciklin, Enrofloksacin, Ertapenem, Eritromicin, Flukloksacilin, Flukonazol, Flucitozin, Fosfomicin, Fusidatnu kiselinu, Garenoksacin, Gatifloksacin, Gemifloksacin, Gentamicin, Imipenem, Itrakonazol, Kanamicin, Ketokonazol, Levofloksacin, Linkomicin, Linezolid, Lorakarbef, Mecilinam (amdinocilin), Meropenem, Metronidazol, Mezlocilin, Mezlocilin-sulbaktam, Minociklin, Moksifloksacin, Mupirocin, Nalidiksinsku kiselinu, Neomicin, Netilmicin, Nitrofurantoin, Norfloksacin, Ofloksacin, Oksacilin, Pefloksacin, Penicilin V, Piperacilin, Piperacilin-sulbaktam, Piperacilintazobaktam, Rifampicin, Roksitromicin, Sparfloksacin, Spektinomicin, Spiramicin, Streptomicin, Sulbaktam, Sulfametoksazol, Teikoplanin, Telavancin, Telitromicin, Temocilin, Tetraciklin, Tikarcilin, Tikarcilin-klavulansku kiselinu, Tigeciklin, Tobramicin, Trimetoprim, Trovafloksacin, Tilozin, Vankomicin, Virginiamicin, Vorikonazol, poželjno se izabire iz grupe koja obuhvaća amoksicilin, klavulansku kiselinu/ampicilin, sulbaktam, fluorokinolon, Sulfametoksazol, trimetoprim, oralni cefalosporin, Nitrofurantoin i Fosfomicin (fosfomicin-trometamol) ili se izabire iz grupe koja obuhvaća trimetoprim, sulfametoksazol, ampicilin, nitrofurantoin i mecilinam (amdinocilin) te njihove kombinacije.
13. Platforma prema zahtjevu 12, gdje je fluorokinolon Ciprofloksacin i/ili gdje je oralni cefalosporin izabran iz grupe koja obuhvaća Cefaleksin, cefuroksim, cefadroksil i cefaklor.
14. Platforma prema bilo kojem od zahtjeva 1 do 13, gdje se polučvrsti medij za rast mikroba izabire iz grupe koja obuhvaća:
i) medij sastava: 11 g/l hidrolizirani kazein, 3 g/l Pepton, 2 g/l Glukoza, 3 g/l Natrijev Klorid, 1 g/l topljivi škrob, 2 g/l Dinatrijev hidrogen Fosfat, 1 g/l Natrijev Acetat, 0.2 g/l Magnezijev glicerofosfat, 0.1 g/l Kalcijev glukonat, 0.001 g/l kobaltov sulfat, 0.001 g/l bakrov sulfat, 0.001 g/l cinkov sulfat, 0.001 g/l željezov sulfat, 0.002 g/l Magnezijev Klorid, 0.001 g/l Menadion, 0.001 g/l Cijanobalamin, 0.02 g/l L-Cistein hidroklorid, 0.02 g/l Triptofan, 0.003 g/l piridoksin, 0.003 g/l pantotenat, 0.003 g/l nikotinamid, 0.0003 g/l Biotin, 0.00004 g/l Tiamin, 0.01 g/l Adenin, 0.01 g/l Gvanin, 0.01 g/l Ksantin, 0.01 g/l Uracil, 8 g/l agar, u destiliranoj vodi;
ii) medij sastava: 2 g Na2HPO4 · 12 H2O, 625 g tripton, 250 g škrob, 833.6 g kalijev Klorid, 2.5 g deterdžent, 74.8 g mesni bujon (Oxoid CM975K), 800g D(+)Glukoza-monohidratae, 1.75 g Ksantin, 1.75 g Gvanin, 17.5 g Magnezijev Sulfat 7 H2O, 19.2 g CaCl2 · 2 H2O, 2,720 g Agar, 5 N HCl do pH 7.4, otopina vitamina i 12.5 1 konjska krv na 250 litara destilirane vode;
iii) medij koji sadrži: 14.5 g/l Pepton, 2 g/l glukoza, 5.5 g/l mješavina soli, 1 g/l topljivi škrob, 1.5 g/l kromogena mješavina, i 8 g/l Agar; te
iv) medij koji sadrži: 2 g/l prah goveđeg ekstrakta/goveđi ekstrakt, 17.5 g/l kiselinom razgrađeni kazein, 1.5 g/l škrob i 17 g/l Agar;
15. Platforma prema bilo kojem od zahtjeva 1 do 14, gdje 3 ili više kromogena supstrata obuhvaćaju 5-Brom-4-klor-3-indolil-β-D-galaktopiranozid, 6-Klor-3-indolil-β-D-galaktopiranozid, 5-Brom-4-klor-3-indolil-β-D-glukopiranozid.
16. Platforma prema bilo kojem od zahtjeva 1 do 14, gdje se tri ili više kromogenih tvari izabire iz grupe koja obuhvaća 6-Klor-3-indolil-β-D-galaktopiranozid, 5-Brom-4-klor-3-indolil-β-D-glukopiranozid, 5-Brom-6-klor-3-indolil-fosfat, 5-Brom-4-klor-3-indolil-β-D-glukuronid i 5-Brom-4-klor-3-indolil-β-D-galaktopiranozid.
17. Platforma prema bilo kojem od zahtjeva 1 do 14, gdje testna i kontrolna smjesa sadrže 6-Klor-3-indolil-β-D-galaktopiranozid u kombinaciji s 5-Brom-4-klor-3-indolil-β-D-glukopiranozidom, 5-Brom-4-klor-3-indolil-β-D-glukuronidom, 5-Brom-4-klor-3-indolil-β-D-galaktopiranozidom i 5-Brom-6-klor-3-indolil fosfatom.
18. Platforma prema bilo kojem od zahtjeva 1 do 14, gdje tri ili više kromogenih tvari obuhvaćaju grupu 5-brom-6-klor-3-indolil-beta-D-galaktopiranozid, 5-brom-4-klor-3-indolil-beta-D-glukopiranozid i 6-klor-3-indolil-beta-D-galaktopiranozid.
19. Platforma prema bilo kojem od zahtjeva 1 do 14, gdje tri ili više kromogenih tvari obuhvaćaju grupu 5-Brom-4-klor-3-indolil-beta-D-galaktopiranozid, 6-klor-3-indolil-beta-D-galaktopiranozid, 5-Brom-4-klor-3-indolil-beta-D-glukopiranozid i 5-Brom-4-klor-3-indolil-beta-D-glukuronid.
20. Platforma prema bilo kojem od zahtjeva 1 do 19, gdje testna smjesa i kontrolna smjesa sadrže četiri kromogena supstrata.
21. Platforma prema bilo kojem od zahtjeva 1 do 20, gdje polučvrsti medij za rast mikroba sadrži 0.25-3.0 g/l triptofana.
22. Platforma prema bilo kojem od zahtjeva 1 do 21, gdje je čvrsta podloga Petrijeva zdjelica podijeljena u 5 testnih odjeljaka i 1 kontrolni odjeljak.
23. Kit koji obuhvaća platformu prema bilo kojem od zahtjeva 1 do 22.
24. Kit prema zahtjevu 23, taj kit dalje obuhvaća standard koji prikazuje količinu rasta na platformi, kao rezultat kontakta te platforme sa suspenzijom koja sadrži unaprijed određeni titar mikrobnog referentnog soja.
25. Kit prema zahtjevu 24 gdje je taj standard fotografska ili tiskana reprodukcija platforme.
26. Kit prema zahtjevu 24 gdje je standard dobiven kontaktom platforme s referentnim sojem bakterije E. coli (po izboru E. coli ATCC 29522), i/ili s referentnim sojem Staphilococcus aureus (po izboru Staphilococcus aureus ATCC 25913).
27. Kit prema zahtjevu 25, taj kit dalje obuhvaća jedno ili više posebno pakiranih anitmikrobnih sredstava.
28. Uporaba platforme prema bilo kojem od zahtjeva 1 do 22 za otkrivanje i/ili dijagnozu infekcija iz grupe koja obuhvaća infekcije mokraćnog trakta, infekcije kože i mekih tkiva, infekcije sa Staphilococcus aureus (uključujući na meticilin rezistentni Staphilococcus aureus), meningokokne infekcije, gonokokne infekcije, infekcije streptokokima uključujući infekcije s pneumokokom.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96926007P | 2007-08-31 | 2007-08-31 | |
EP07115480 | 2007-08-31 | ||
PCT/DK2008/000303 WO2009026920A1 (en) | 2007-08-31 | 2008-08-26 | Compositions and means for diagnosing microbial infections |
EP08784426.2A EP2181330B2 (en) | 2007-08-31 | 2008-08-26 | Compositions and means for diagnosing microbial infections |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20140019T1 HRP20140019T1 (en) | 2014-02-14 |
HRP20140019T4 true HRP20140019T4 (hr) | 2017-03-10 |
Family
ID=38961445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140019TT HRP20140019T4 (hr) | 2007-08-31 | 2014-01-07 | Smjese i sredstva za dijagnozu mikrobnih infekcija |
Country Status (13)
Country | Link |
---|---|
US (1) | US8753875B2 (hr) |
EP (1) | EP2181330B2 (hr) |
CN (1) | CN101790683B (hr) |
BR (1) | BRPI0815321A2 (hr) |
CA (1) | CA2698318C (hr) |
DK (1) | DK2181330T4 (hr) |
ES (1) | ES2446943T5 (hr) |
HR (1) | HRP20140019T4 (hr) |
IL (1) | IL203828A (hr) |
PL (1) | PL2181330T5 (hr) |
PT (1) | PT2181330E (hr) |
SI (2) | SI2181330T1 (hr) |
WO (1) | WO2009026920A1 (hr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100227338A1 (en) * | 2007-03-22 | 2010-09-09 | Nanologix, Inc. | Method and Apparatus for Rapid Detection and Identification of Live Microorganisms Immobilized On Permeable Membrane by Antibodies |
WO2010010083A1 (en) | 2008-07-21 | 2010-01-28 | Alain Rambach | Selective enrichment medium for carbapenem-resistant bacteria |
FR2973041A1 (fr) * | 2011-03-25 | 2012-09-28 | Biomerieux Sa | Detection de bacteries presentant une resistance enzymatique aux carbapenemes |
ES2652367T3 (es) * | 2011-06-03 | 2018-02-01 | Universidade Do Porto | Método de detección de los microorganismos resistentes a un agente terapéutico |
WO2013004779A1 (en) * | 2011-07-05 | 2013-01-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Selective culture medium and method for detecting carbapenem-resistant bacteria in a test sample |
GB201120991D0 (en) | 2011-12-07 | 2012-01-18 | Univ Manchester | Microsensor |
US8921068B2 (en) * | 2012-04-30 | 2014-12-30 | Cl Solutions, Llc | Detection of microorganisms involved in metabolism of organic environmental pollutants |
FR2993900B1 (fr) * | 2012-07-27 | 2016-03-25 | Biomerieux Sa | Procede de detection de bacteries productrices de carbapenemases de type oxa-48 |
GR1008010B (el) * | 2012-08-24 | 2013-10-16 | Μανουσος Εμμανουηλ Καμπουρης | Τρυβλιο διαφορικων συγχρονων καλλιεργειων |
RU2505813C1 (ru) | 2012-11-06 | 2014-01-27 | Виктор Вениаминович Тец | Способ определения чувствительности микроорганизмов к антимикробным веществам |
FR3000501B1 (fr) | 2012-12-28 | 2015-08-14 | Biomerieux Sa | Milieu de detection de micro-organismes comprenant au moins un alkyl(thio)glycoside |
CN103941000B (zh) * | 2013-01-19 | 2016-08-31 | 北京勤邦生物技术有限公司 | 一种检测磺胺类药物和氟喹诺酮类药物的试纸条及方法 |
US10138451B2 (en) * | 2013-01-30 | 2018-11-27 | Christopher B. REID | Cell culture dish supporting simultaneously juxtaposed and separated cultures |
FR3004195B1 (fr) | 2013-04-03 | 2017-10-06 | Biomerieux Sa | Utilisation d'au moins un substrat de phosphatase chromogene et/ou fluorogene pour la detection et/ou le denombrement d'enterobacteries dans un echantillon biologique. |
CN103642894B (zh) * | 2013-11-25 | 2016-04-20 | 广东环凯微生物科技有限公司 | 一种金黄色葡萄球菌特异性显色培养基 |
EP3075840B1 (en) * | 2013-11-28 | 2018-10-17 | Viktor Veniaminovich Tets | Device for determining the sensitivity of microorganisms to antimicrobial drugs |
CN104597099A (zh) * | 2013-12-20 | 2015-05-06 | 上海迪安医学检验所有限公司 | 一种防腐琼脂糖凝胶板的制备方法 |
TWI540207B (zh) * | 2014-01-20 | 2016-07-01 | 國立清華大學 | 細菌培養暨檢測裝置和方法 |
FR3024465B1 (fr) * | 2014-07-30 | 2018-03-23 | Biomerieux | Caracterisation de micro-organismes par maldi-tof |
WO2016081592A1 (en) * | 2014-11-18 | 2016-05-26 | Fleurir Abx Llc | Combination therapy effective against microorganisms, including drug resistant microorganisms |
RU2604789C1 (ru) | 2015-06-23 | 2016-12-10 | Виктор Вениаминович Тец | Питательная среда для выращивания бактерий |
WO2018171009A1 (zh) * | 2017-03-22 | 2018-09-27 | 珠海美华医疗科技有限公司 | 一种平盖式真菌培养装置 |
CN106834116A (zh) * | 2017-04-07 | 2017-06-13 | 珠海美华医疗科技有限公司 | 一种临床致病菌的鉴定装置 |
WO2018222061A1 (en) | 2017-06-02 | 2018-12-06 | Fastinov S.A. | Improved therapeutic drug monitoring |
CN108387536A (zh) * | 2018-01-31 | 2018-08-10 | 佛山市南海东方澳龙制药有限公司 | 硫酸头孢喹肟乳房注入剂(泌乳期)含量的快速测定方法 |
JP2023522149A (ja) * | 2020-03-20 | 2023-05-29 | カヴァロパウロス,ニコラオス | 化学物質相互作用効果の判定 |
US11781105B2 (en) * | 2020-06-05 | 2023-10-10 | National Guard Health Affairs | Method, system, and apparatus using centrifugation to accumulate and collect biological samples |
US11925653B2 (en) | 2021-01-25 | 2024-03-12 | Fleurir Abx, Llc | Combination therapy effective against microorganisms, including drug resistant microorganisms |
US20230398101A1 (en) * | 2022-06-09 | 2023-12-14 | Fleurir Abx Llc | Co-agents as Therapy Against Anaerobic Pathogens |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5534415A (en) * | 1991-11-25 | 1996-07-09 | Bio Merieux | Selective and differential medium for the growth and detection of Candida albicans |
DE4316394C1 (de) * | 1993-05-17 | 1994-06-23 | Biotest Ag | Verfahren zum optischen Nachweis von Mikroorganismen, ihrer Identifizierung und der Empfindlichkeitstestung gegen Antibiotika unter Verwendung eines Redoxindikatorsystems, umfassend Methylenblau und Resazurin |
FR2708286B1 (fr) * | 1993-07-28 | 1995-10-20 | Rambach Alain | Procédé d'identification de microorganismes avec au moins deux chromogènes. |
US5443963A (en) * | 1994-01-31 | 1995-08-22 | Minnesota Mining And Manufacturing Company | Method for detecting staphylococci |
US5464739A (en) * | 1994-08-22 | 1995-11-07 | Bayer Corporation | Composition method for determining the presence of leukocyte cells, esterase or protease in a test sample |
AU5939396A (en) * | 1995-06-07 | 1996-12-30 | Biolog, Inc. | Microbiological media for isolation and identification of en teric pathogens such as e. coli and salmonella |
US5958675A (en) * | 1997-04-18 | 1999-09-28 | 3M Innovative Properties Company | Method for detecting bacteria using bacteriophage, contrast-coloring dye and precipitable dye |
US6984499B2 (en) * | 1997-10-02 | 2006-01-10 | Idexx Laboratories, Inc. | Method and apparatus for concurrently detecting pathogenic organisms and antimicrobial susceptibility |
US6251624B1 (en) * | 1999-03-12 | 2001-06-26 | Akzo Nobel N.V. | Apparatus and method for detecting, quantifying and characterizing microorganisms |
US6350588B1 (en) | 1999-07-20 | 2002-02-26 | Micrology Laboratories, Llc | Test media and quantitative or qualitative method for identification and differentiation of biological materials in a test sample |
US6750038B1 (en) * | 2000-09-28 | 2004-06-15 | Essential Therapeutics, Inc. | Rapid antibiotic susceptibility test |
US7384778B2 (en) * | 2002-01-10 | 2008-06-10 | Idexx Laboratories, Inc. | Methods and devices for the detection of pathogenic microorganisms and their antimicrobial susceptibility |
WO2004050675A1 (en) * | 2002-12-03 | 2004-06-17 | Read Robert Taintor | Concurrent microorganism identification and susceptibilities from broth |
-
2008
- 2008-08-26 SI SI200831128T patent/SI2181330T1/sl unknown
- 2008-08-26 CN CN200880104753.XA patent/CN101790683B/zh active Active
- 2008-08-26 EP EP08784426.2A patent/EP2181330B2/en active Active
- 2008-08-26 SI SI200831128A patent/SI2181330T2/sl unknown
- 2008-08-26 DK DK08784426.2T patent/DK2181330T4/en active
- 2008-08-26 PL PL08784426T patent/PL2181330T5/pl unknown
- 2008-08-26 WO PCT/DK2008/000303 patent/WO2009026920A1/en active Application Filing
- 2008-08-26 CA CA2698318A patent/CA2698318C/en active Active
- 2008-08-26 ES ES08784426.2T patent/ES2446943T5/es active Active
- 2008-08-26 PT PT87844262T patent/PT2181330E/pt unknown
- 2008-08-26 BR BRPI0815321-3A2A patent/BRPI0815321A2/pt not_active Application Discontinuation
- 2008-11-04 US US12/198,542 patent/US8753875B2/en active Active
-
2010
- 2010-02-09 IL IL203828A patent/IL203828A/en active IP Right Revival
-
2014
- 2014-01-07 HR HRP20140019TT patent/HRP20140019T4/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2181330B2 (en) | 2016-08-31 |
DK2181330T4 (en) | 2016-11-28 |
CN101790683A (zh) | 2010-07-28 |
US8753875B2 (en) | 2014-06-17 |
EP2181330A1 (en) | 2010-05-05 |
DK2181330T3 (da) | 2014-01-27 |
EP2181330B1 (en) | 2013-11-20 |
CA2698318A1 (en) | 2009-03-05 |
SI2181330T2 (sl) | 2016-11-30 |
HRP20140019T1 (en) | 2014-02-14 |
IL203828A (en) | 2013-12-31 |
CN101790683B (zh) | 2015-02-11 |
ES2446943T3 (es) | 2014-03-10 |
BRPI0815321A2 (pt) | 2015-02-10 |
CA2698318C (en) | 2015-09-29 |
PL2181330T3 (pl) | 2014-04-30 |
WO2009026920A1 (en) | 2009-03-05 |
SI2181330T1 (sl) | 2014-04-30 |
ES2446943T5 (es) | 2017-03-14 |
PT2181330E (pt) | 2014-02-21 |
PL2181330T5 (pl) | 2017-07-31 |
US20090068696A1 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140019T4 (hr) | Smjese i sredstva za dijagnozu mikrobnih infekcija | |
Takesue et al. | Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan | |
Rice | Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa | |
Perry et al. | Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections | |
Sumita et al. | In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338 | |
WO2008039420A3 (en) | Novel inhibitors of beta-lactamase | |
JP2018525434A5 (hr) | ||
CN110997930A (zh) | 用于综合鉴定抗生素敏感性的测定方法 | |
Bosso | The antimicrobial armamentarium: evaluating current and future treatment options | |
JP6480870B2 (ja) | 細菌感染を処置するための組成物および方法 | |
Kuriyama et al. | Antimicrobial chemotherapy: Significance to healthcare | |
Doern et al. | In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods | |
CA2835907C (en) | Compositions comprising antibacterial agent and tazobactam | |
Matsumoto et al. | Newer carbapenems for urinary tract infections | |
Chaudhary et al. | Catering ESBL resistance challenge through strategic combination of ceftriaxone, sulbactam and ethylene diamine tetraacetic acid | |
Khajuria et al. | Emergence of VIM-6 metallo-beta-lactamase-producing Alcaligenes faecalis clinical isolates in a hospital in India | |
Lee et al. | Management of antibiotic-resistant acute pyelonephritis | |
Nikolov et al. | New antimicrobial drugs. | |
Kern | Antibacterial agents | |
Kumar et al. | PREVALENCE OF VARIOUS β-LACTAMASE (ESBL, AMPC AND MBL) PRODUCING MULTIDRUG RESISTANT CLINICAL ISOLATES OF ACINETOBACTER SPP. IN A TERTIARY CARE HOSPITAL. | |
JP2001321156A (ja) | 薬剤感受性試験用プレート | |
CN114129564B (zh) | 依帕司他或其药学上可接受的盐在制备预防和/或治疗细菌感染疾病药物中的应用 | |
Carlson | Comparison of the E test and agar dilution methods for susceptibility testing of Arcanobacterium haemolyticum | |
Almaghrabi | Dominant multidrug‐resistant bacteria in five biggest hospitals in Asir Region from March to June 2018 | |
US20230093073A1 (en) | Methods and compositions for community-based screening of polymicrobial infections |